1- Coleman RE.
Metastati
c bone disease: clinical
features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27(3): 165-76.
2- Gracia-Sanez JA, Lopez-Tarruella S, Gracia-Paredes
B, Rodriguez-Lajusticia L, Villalobos L, Diaz-Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Pathol Oral Cir Bucal
2007; 12(5): E351-6.
3- Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell
CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK. A double blind, placebo controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (mrc pr05Trail). J Natl Cancer 2003; 95(17): 1300-11.
4- Fleisch H. Development of bisphosphonates. Breast
Cancer Res 2002; 4(1):30-4.
5- Fleish H. Bisphosphonates: mechanisms of action.
Endocr Rev 1998; 19(1): 80-100.
6- Lobato JV, Mauricio AC, Rodgigues JM, Cavaleiro
MV, Cortez PP, Xavier L, Botelho C, Hussain NS, Santos JD. Jaw avasculer osteonecrosis after treatment of multiple myeloma with zoledronate. J Plast Reconstr Aesthet Surg 2008; 61(1):99-106.
7- Walter C, Grötz GA, Kunkel M, Al-Nawas B.
Prevlance of bifosfonat associated osteoncrosis of the jaw within field of osteonecrosis. Support Care
Cancer 2007; 15(2): 197-202.
Atatürk Üniv. Diş Hek. Fak. Derg.
Cilt: 18, Sayı: 3, Yıl: 2008, Sayfa: 105-110
8- Lin JH. Bisphosphonates: a review of their
pharmacokinetic properties. Bone 1996; 18(2): 75¬85.
9- Hughes DE,
MacDonal
d BR, Russell RG, Gowen M.
Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83(6): 1930-5.
10- Hughes DE, Wright KR Uy HL. Sasaki A, Yoneda T. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Mineral Res 1995; 10(10): 1478-87.
11- Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17(2): 137-44.
12- Reilly MM. Osteonecrosis of the jaw in a patient receiving bisphosphonate therapy. Oncol Nurs
Forum 2007; 34(2):301-5.
13- Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34):8580-7.
14- Woo SK, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the
jaws. Ann Inter Med 2006; 144 (10): 753-61.
15- Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005 Jul 1;104(1):83-93.
16- Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;
96(11):879-82.
17- Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, Gilardino MO, Aglietta M. Osteonecrosis of the jaws in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol
2007; 46(5): 664-8.
18- Ergün S, Güneri P, Koca H. Çene kemiklerinin yeni tehlikesi: Bifosfonatlar. Cumhuriyet Üniversitesi Diş Hekimliği Fakültesi Derg 2008; 11(2): 140-45.
ZAFERSOY AKARSLAN, ALTUNDAĞ KAHRAMAN
19- Phal PM,
Myal
l RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws Am J Neuroradiol 2007;
28(6):1139-45.
20- Ruggiero S, Gralow J, Marx R, Hoff A, Schubert M, et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac 2006;
2(1): 7-14.
21- Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63(11):1567-75.
22- Şenel-Çizmeci F, Baltacıoğlu E, Basmacı-Çizmeci F, Bağış B, Özkaynak Ö, Tosun E. Bifosfonat kullanımına bağlı gelişen mandibula ve maksilla nekrozları ve dental yaklaşım. ADO Klinik Bilimleri
Derg 2007; 4(1): 49-54.
23- Melo MD,
Obei
d G. Osteonecrosis in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition.
JADA 2005; 136(12): 1675-81.
24- Curi MM, Cossolin GS, Koga DH, Araujo SR, Feher O, Dos Santos MO, Zardetto C. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 2007; 65(2):349-55.
25- Cetiner S, Sucak GT, Kahraman SA, Akı SZ, Kocakahyaoglu B, Gultekin SE, Cetiner M, Haznedar R. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 2009; yayına kabuledildi. Online DOI: 10.1007/s00774-009-0047-9.
Thank you for copying data from http://www.arastirmax.com
